Fenretinide In Treating Patients With Advanced or Metastatic Hormone-Refractory Prostate Cancer
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as fenretinide, work in different ways to stop
tumor cells from dividing so they stop growing or die.
PURPOSE: This phase II trial is studying how well fenretinide works in treating patients with
advanced or metastatic hormone-refractory prostate cancer.